

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
HALAZONETIS, et al.) Attorney Docket No. 02973.00031
Divisional of Serial No.: 08/894,327,) Group Art Unit: Unknown
filed December 4, 1997) Examiner: Unknown
Filed: Herewith 4-11-2001)

For: PEPTIDES AND PEPTIDOMIMETICS WITH STRUCTURAL SIMILARITY TO
HUMAN p53 THAT ACTIVATES p53 FUNCTION

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to their duty of good faith and candor as set forth in 37 C.F.R. § 1.56(a) Applicants submit herewith the attached Form PTO 1449 citing previously submitted references. Copies of the references cited are not submitted herewith, but can be found in parent application file U.S. Serial No. 08/894,327.

Applicants respectfully request that the Examiner consider and enter these references into the file of this application and return a signed copy of Form PTO 1449 indicating the same.

It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,



Ajay Pathak
Registration No. 38,266

Date: April 11, 2001

BANNER & WITCOFF, LTD.
1001 G Street, N.W., 11th Floor
Washington, DC 20001
Tel: (202) 508-9100
Fax: (202) 508-9299
AP:lab
386061_1.DOC

USPTO Form 1440 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 02973.00031	Serial No. TBA		
INFORMATION DISCLOSURE CITATION Sheet 1 of 2		Applicant(s): Thanos HALAZONETIS et al.			
		Filing Date: Herewith	Group:		
U.S. PATENT DOCUMENTS					
Examiner Initial	Patent No.	Date	Name	Class	Subclass
					Filing Date (if appropriate)
FOREIGN PATENT DOCUMENTS					
Examiner Initial	Document No.	Date	Country	Class	Subclass
	94/08241	4/1994	WO		
	95/17213	6/1995	WO		
	0 518 650	12/1992	EP		
	94/12202	1994	WO		
	94/10306	5/1994	WO		
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)					
	Coller et al., "Substituting Isoserine for Serine in the Thrombin Receptor Activation Peptide SFLLRN Confers Resistance to Aminopeptidase M-induced Cleavage and Inactivation," <i>J. Biol. Chem.</i> , 268(28):20741-20743 (1993)				
	Couder et al., "Synthesis and Biological Activities of $\psi(\text{CH}_2\text{NH})$ Pseudopeptide Analogues of the C-terminal Hexapeptide of Neurotensin," <i>Internat. J. Peptide & Protein Res.</i> , 41(2):181-184 (1993)				
	DalPozzo et al., "H-Gly-His $\psi(\text{NHCO})$ Lys-OH, Partially Modified Retro-Inverso Analogue of the Growth Factor Glycyl-L-histidyl-l-lysine with Enhanced enzymatic Stability," <i>Int. J. Peptide Protein Res.</i> , 41:561-566 (1993)				
	Hupp et al., "Regulation of the Cryptic Sequence-Specific DNA-Binding Function of p53 by Protein Kinases," <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , Vol. LIX, pp. 195-205 (1994)				
	Hupp et al., "Small Peptides Activate the Latent Sequence-Specific DNA Binding Function of p53," <i>Cell</i> , 83:237-245 (1995)				
	Shaw et al., "Regulation of Specific DNA Binding by p53: Evidence for a Role of o-Glycosylation and Charged Residues at the Carboxy-terminus," <i>Oncogene</i> , 12:921-930 (1996)				
	Takenaka et al., "Regulation of the Sequence-Specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases," <i>J. Biol. Chem.</i> , 270(10):5405-5411 (1995)				
	Tanigaki et al., "The Peptide Binding Specificity of HLA-B27 Subtypes," <i>Immunogenetics</i> , 40:192-198 (1994)				
	Powell et al., "Peptide Stability in Drug Development. II. Effect of Single Amino acid Substitution and Glycosylation on Peptide Reactivity in Human Serum," <i>Pharmaceutical Research</i> , 10(9):1268-1273 (1993)				
	Brady et al., "Reflections on a Peptide," <i>Nature</i> , 368:692-693 (1994)				
	Hupp et al., "Allosteric Activation of Latent p53 Tetramers," <i>Current Biology</i> , 4(10):865-875 (1994)				
	Wade-Evans et al., "Precise Epitope Mapping of the Murine Transformation-Associated Protein, p53," <i>EMBO J.</i> , 4:699-706 (1985)				
	Finlay et al., "The p53 Proto-Oncogene Can Act as a Suppressor of Transformation," <i>Cell</i> , 57:1083-1093 (1989)				
	Soussi et al., "Structural Aspects of the p53 Protein in Relation to Gene Evolution," <i>Oncogene</i> , 5:945-952 (1990)				
	Hupp et al., "Regulation of the Specific DNA Binding Function of p53," <i>Cell</i> , 71:857-886 (1992)				
	Hruby, "Conformational and Topographical Consideration in the Design of Biologically Active Peptides," <i>Biopolymers</i> , 33:1073-1082 (1993)				

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 02973.00031	Serial No. TBA
INFORMATION DISCLOSURE CITATION Sheet 1 of 2		Applicant(s): Thanos HALAZONETIS et al.	
		Filing Date: Herewith	Group:
<p>Hupp et al., "Activation of the Cryptic DNA Binding Function of Mutant Forms of p53," <i>Nucleic Acids Res.</i>, 21:3167-3174 (1993)</p> <p>Fujiwara et al., "A Retroviral Wild-Type p53 Expression Vector Penetrates Human Lung Cancer Spheroids and Inhibits Growth by Inducing Apoptosis," <i>Cancer Res.</i>, 53:4129-4133 (1993)</p> <p>Halazonetis et al., "Wild-Type p53 Adopts a 'Mutant'-like Conformation when Bound to DNA," <i>EMBO J.</i>, 12:1021-1028 (1993)</p> <p>Halazonetis et al., "Conformational Shifts Propagate from the Oligomerization Domain of p53 to its Tetrameric DNA Binding Domain and Restore DNA Binding to Select p53 Mutants," <i>EMBO J.</i>, 12:5057-5064 (1993)</p> <p>Bugg et al., "Drugs by Design," <i>Sci. Am.</i>, 269:92-98 (1993)</p> <p>Friend, "p53: A Glimpse at the Puppet Behind the Shadow Play," <i>Science</i>, 265:334-335 (1994)</p> <p>Cho et al., "Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations," <i>Science</i>, 265:346-355 (1994)</p> <p>Clore et al., "High Resolution Structure of the Oligomerization Domain of p53 by Multidimensional NMR," <i>Science</i>, 265:386-391 (1994)</p> <p>Speir et al., "Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis," <i>Science</i>, 265:391-394 (1994)</p> <p>Cox et al., "Xenopus p53 is Biochemically Similar to the Human Tumour Suppressor Protein p53 and is Induced upon DNA Damage in Somatic Cells," <i>Oncogene</i>, 9:2951-2959 (1994)</p> <p>Jameson et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis," <i>Nature</i>, 368:744-746 (1994)</p> <p>Moore, "Designing Peptide Mimetics," <i>Trends Pharmacol. Sci.</i>, 15:124-129 (1994)</p> <p>Dean, "Recent Advances in Drug Design Methods" Where Will They Lead?" <i>BioEssays</i>, 16:683-687 (1994)</p> <p>Naoko Arai et al., "Immunologically Distinct p53 Molecules Generated by Alternative Splicing," <i>Molecular and Cellular Biology</i>, Vol 6, No. 9, September 1986, p. 3232-3239</p> <p>Stryer. <i>Biochemistry</i> Second Edition, p. 13-17</p>			
EXAMINER		DATE CONSIDERED	
<p>*EXAMINER: Initial if reference considered. Whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p> <p>**Copies of references not provided at the time of this submission.</p>			